Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients

Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients

Anti-PD-1 antibodies prolong survival of performance status (PS) 0–1 advanced non-small-cell lung cancer (aNSCLC) patients. Their efficacy in PS 3–4 patients is unknown. Conse- cutive PS 3–4 aNSCLC patients receiving compassionate nivolumab were accrued by 12 French thoracic oncology departments, ov...

Full description

Bibliographic Details
Main Authors: Valérie Gounant, Michael Duruisseaux, Ghassen Soussi, Sylvie Van Hulst, Olivier Bylicki, Jacques Cadranel, Marie Wislez, Jean Trédaniel, Jean-Philippe Spano, Carole Helissey, Christos Chouaid, Olivier Molinier, Xavier Dhalluin, Ludovic Doucet, José Hureaux, Aurélie Cazes, Gérard Zalcman
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cancers
Subjects:
non-small cell lung cancer
poor performance status
immunotherapy
nivolumab
brain metastases
Online Access:https://www.mdpi.com/2072-6694/13/5/1040

Internet

https://www.mdpi.com/2072-6694/13/5/1040

Similar Items